An Overview of Phenylcyclopropylamine Derivatives: Biochemical and Biological Significance and Recent Developments

Medicinal Research Reviews

Volumn 33, Issue 4, 2013, Pages 873-910

  Khan, Mohammed Naseer Ahmed ^a   Suzuki, Takayoshi ^a,b,c   Miyata, Naoki ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Anticancer; Drug design and development; Enzyme inhibition; LSDs; MAOs; Phenylcyclopropylamines; Structure activity relationships

Indexed keywords

2 (2 HYDROXYPHENYL)N,N DI N PROPYLCYCLOPROPYLAMINE; 2 (3 HYDROXYPHENYL)N,N DI N PROPYLCYCLOPROPYLAMINE; 2 FLUORO 2 ARYLCYCLOPROPYLAMINE; 2 FLUORO 2 PHENYLCYCLOPROPYLAMINE; 4 PHENYLCYCLOPROPYLAMINE QUINAZOLINE CONJUGATE; AMINE OXIDASE (COPPER CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CYTOCHROME P450; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOXIDE HYDROLASE; LYSINE SPECIFIC DEMETHYLASE; MONOAMINE OXIDASE INHIBITOR; QUINAZOLINE; RNA DIRECTED DNA POLYMERASE; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SIGMA 1 OPIATE RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANYLCYPROMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CATECHOLAMINE NERVE CELL; CELL GROWTH; CELL MIGRATION; COLORECTAL CANCER; CRYSTAL STRUCTURE; DEPRESSION; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; ELECTRON TRANSPORT; ELECTROSPRAY MASS SPECTROMETRY; ENANTIOMER; ENZYME INHIBITION; ENZYME STRUCTURE; GLIA CELL; HUMAN; IC 50; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; LUNG SMALL CELL CANCER; MEDULLOBLASTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXIDATION; PANCREAS CANCER; PARKINSON DISEASE; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; THERAPY EFFECT;

CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; SIGNAL TRANSDUCTION; TRANYLCYPROMINE;

EID: 84878667982     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21269     Document Type: Article

References (148)

1. Burger A, Yost WL. Arylcycloalkylamines. I. 2-Phenylcyclopropylamine. J Am Chem Soc 1948;70:2198-2201.
2. Tedeschi RE, Tedeschi DH, Ames PL, Cook L, Mattis PA, Fellows EJ. Some pharmacological observations on tranylcypromine (SKF trans-385); a potent inhibitor of monoamine oxidase. Proc Soc Exptl Biol Med 1959;102:380-381.
3. Tedeschi DH, Tedeschi RE, Fellows EJ. The effect of tryptamine on the central nervous system, including a pharmacological procedure for the evaluation of iproniazid-like drugs. J Pharmacol Exptl Ther 1959;126:223-232.
4. Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics, 5th edition. New York: MacMillan Publishing Co.; 1975. p 180.
5. Taylor JB, Kennewell PD. Introductory Medicinal Chemistry. Chichester: Ellis Honvood Ltd.; 1981. p 20.
6. Smith DF. Tranylcypromine stereoisomers, monoaminergic neurotransmission and behavior. A minireview. Pharmakopsychiatr Neuro-Psychopharmakol 1980;13:130-136.
7. Weber-Grandke H, Hahn G, Mutschler E, Mohrke W, Langguth P, Spahn-Langguth H. The pharmacokinetics of tranylcypromine enantiomers in healthy subjects after oral administration of racemic drug and the single enantiomers. Br J Clin Pharmacol 1993;36:363-365.
8. Frieling H, Bleich S. Tranylcypromine: New perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci 2006;256:268-273.
9. Schmidt DM, McCafferty DG. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007;46:4408-4416.
10. Yang M, Culhane JC, Szewczuk LM, Jalili P, Ball HL, Machius M, Cole PA, Yu H. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry 2007;46:8058-8065.
11. Mimasu S, Sengoku T, Fukuzawa S, Umehara T, Yokoyama S. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Biochem Biophys Res Commun 2008;366:15-22.
12. Binda C, Valente S, Romanenghi M, Pilotto S, Cirilli R, Karytinos A, Ciossani G, Botrugno OA, Forneris F, Tardugno M, Edmondson DE, Minucci S, Mattevi A, Mai A. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc 2010;132:6827-6833.
13. Mallinger AG, Himmelhoch JM, Thase ME, Edwards DJ, Knopf S. Plasma tranylcypromine: Relationship to pharmacokinetic variables and clinical antidepressant actions. J Clin Psychopharmacol 1990;10:176-183.
14. Paech C, Salach JI, Singer TP. Suicide inactivation of monoamine oxidase by trans-phenylcyclopropylamine. In: Singer TP, Von Korff RW, Murphy DL, Eds. Monoamine Oxidase: Structure, Function, and Altered Functions. New York: Academic Press; 1979. p 39-50.
15. Moises HW, Beckmann H. Antidepressant efficacy of tranylcypromine isomers: A controlled study. J Neural Transm 1981;50:185-192.
16. Horn AS, Snyder SH. Steric requirements for catecholamine uptake by rat brain synaptosomes: Studies with rigid analogs of amphetamine. J Pharmacol Exp Ther 1972;180:523-530.
17. Erhardt PW, Gorczynski RJ, Anderson WG. Conformational analogues of dopamine. Synthesis and pharmacological activity of (E)- and (Z)-2-(3, 4-dihydroxyphenyl)cyclopropylamine hydrochlorides. J Med Chem 1979;22:907-911.
18. Nichols DE, Woodard R, Hathaway BA, Lowy MT, Yom KW. Resolution and absolute configuration of trans-2-(2, 5-dimethoxy-4-methylphenyl)cyclopropylamine, a potent hallucinogen analogue. J Med Chem 1979;22:58-460.
19. Aldous FA, Barrass BC, Brewster K, Buxton DA, Green DM, Pinder RM, Rich P, Skeels M, Tutt KJ. Structure-activity relationships in psychotomimetic phenylalkylamines. J Med Chem 1974;7:1100-1111.
20. Singer TP, Ramsay RR. Flavoprotein structure and mechanism 2. Monoamine oxidases: Old friends hold many surprises. FASEB J 1995;9:605-610.
21. Knoll K. Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases. Med Res Rev 1992;12:505-524.
22. Robinson DS. Enzymes as targets for drug design. In: Palfreyman MG, McCann PP, Lovenberg W, Temple JG, Sjoerdsma A. Eds. San Diego: Academic Press; 1989. p 233-257.
23. Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC. cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 1988;85:4934-4938.
24. Minamiura N, Yasunobu KT. Bovine liver monoamine oxidase. A modified purification procedure and preliminary evidence for two subunits and one FAD. Arch Biochem Biophys 1978;189:481-489.
25. Weyler W, Salach JI. Purification and properties of mitochondrial monoamine oxidase type A from human placenta. J Biol Chem 1985;260:13199-13207.
26. Grimsby J, Lan NC, Neve R, Chen K, Shih JC. Tissue distribution of human monoamine oxidase A and B mRNA. J Neurochem 1990;55:1166-1169.
27. Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem 1986;46:1359-1365.
28. Paech C, Salach JI, Singer TP. Suicide inactivation of monoamine oxidase by trans-phenylcyclopropylamine. J Biol Chem 1980;255:2700-2704.
29. Silverman BR. Mechanism of inactivation of monoamine oxidase by trans-2-phenylcyclopropylamine and the structure of the enzyme-inactivator adduct. J Biol Chem 1983;258:14766-14769.
30. Binda C, Li M, Hubalek F, Restelli N, Edmondson DE, Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA 2003;100:9750-9755.
31. Bonivento D, Milczek EM, McDonald GR, Binda C, Holt A, Edmondson DE, Mattevi A. Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J Biol Chem 2010;285:36849-36856.
32. Silverman RB, Zieske PA. Mechanism of inactivation of monoamine oxidase by 1-phenylcyclopropylamine. Biochemistry 1985;24:2128-2138.
33. Silverman RB, Zieske PA. Identification of the amino acid bound to the labile adduct formed during inactivation of monoamine oxidase by 1-phenylcyclopropylamine. Biochem Biophys Res Commun 1986;135:154-159.
34. Silverman RB, Cesarone JM, Lu X. Stereoselective ring opening of 1-phenylcyclopropylamine catalyzed by monoamine oxidase-B. J Am Chem Soc 1993;115:4955-4961.
35. Nagy J, Kenney WC, Singer TP. The reaction of phenylhydrazine with trimethylamine dehydrogenase and with free flavins. J Biol Chem 1979;254:2684-2688.
36. Maycock AL, Abeles RH, Salach JI, Singer TP. The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavine of mitochondrial amine oxidase. Biochemistry 1976;15:114-125.
37. Mitchell DJ, Nikolic D, Rivera E, Sablin SO, Choi S, van Breemen RB, Singer TP, Silverman RB. Spectrometric evidence for the flavin-1-phenylcyclopropylamine inactivator adduct with monoamine oxidase N. Biochemistry 2001;40:5447-5456.
38. Schilling B, Lerch K. Amine oxidases from Aspergillus niger: Identification of a novel flavin-dependent enzyme. Biochim Biophys Acta 1995;1243:529-537.
39. Walker WH, Hemmerich P, Massey V. Reduktive Photoalkylierung des Flavinkerns und Flavinkatalysierte Photodecarboxylierung von Phenylacetat Studien in der Flavinreihe. 15. Helv Chim Acta 1967;50:2269-2279.
40. Kaiser C, Lester BM, Zirkle CL, Burger A, Davis CS, Della TJ, Zirngibl L. 2-Substituted cyclopropylamines. I. Derivatives and analogues of 2-phenylcyclopropylamine. J Med Pharm Chem 1962;5:1243-1265.
41. Zirkle CL, Kaiser C, Tedeschi DH, Tadeshi DH, Tedeschi RE, Burger A. 2-Substituted cyclopropylamines. II. Derivatives and analogues of 2-phenylcyclopropylamine. J Med Pharm Chem 1962;5:1265-1284.
42. Neff NH, Yang HY. Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci 1974;14:2061-2074.
43. Kang GI, Hong SK. Quantitative structure-activity relationships in MAO-inhibitory 2-phenylcyclopropylamines: Insights into the topography of MAO-A and MAO-B. Arch Pharm Res 1990;13:82-96.
44. Pignatello R, Puleo A, Guccione S, Raciti G, Acquaviva R, Campisi A, Ventura CA, Puglisi G. Enhancement of drug affinity for cell membranes by conjugation with lipoamino acids. I. Synthesis and biological evaluation of lipophilic conjugates of tranylcypromine. Eur J Med Chem 2005;40:1074-1079.
45. Desino KE, Pignatello R, Guccione S, Basile L, Ansar S, Michaelis ML, Ramsay RR, Audus KL. TCP-FA4: A derivative of tranylcypromine showing improved blood-brain permeability. Biochem Pharmacol 2009;78:1412-1417.
46. Elmore BO, Bollinger JA, Dooley DM. Human kidney diamine oxidase: Heterologous expression, purification, and characterization. J Biol Inorg Chem 2002;7:565-579.
47. Plastino J, Green EL, Sanders-Loehr J, Klinman JP. An unexpected role for the active site base in cofactor orientation and flexibility in the copper amine oxidase from Hansenula polymorpha. Biochemistry 1999;38:8204-8016.
48. Wilce MC, Dooley DM, Freeman HC, Guss JM, Matsunami H, McIntire WS, Ruggiero CE, Tanizawa K, Yamaguchi H. Crystal structures of the copper-containing amine oxidase from Arthrobacter globiformis in the holo and apo forms: Implications for the biogenesis of topaquinone. Biochemistry 1997;36:16116-16133.
49. Kagan HM. Lysyl oxidase: Mechanism, regulation and relationship to liver fibrosis. Pathol Res Pract 1994;190:910-919.
50. Wang SX, Mure M, Medzihradszky KF, Burlingame AL, Brown DE, Dooley DM, Smith AJ, Kagan HM, Klinman JP. A crosslinked cofactor in lysyl oxidase: Redox function for amino acid side chains. Science 1996;273:1078-1084.
51. Kagan HM. Characterization and regulation of LO. Mecham RP, Ed. In Biology of the Extracellular Matrix. Orlando, FL: Academic Press; 1986. p 321-398.
52. Wiseman JS, Abeles RH. Mechanism of inhibition of aldehyde dehydrogenase by cyclopropranone hydrate and the mushroom toxin coprine. Biochemistry 1979;18:427-435.
53. Crabbe MJ, Bardsley WG. Monoamine oxidase inhibitors and other drugs as inhibitors of diamine oxidase from human placenta and pig kidney. Biochem Pharmacol 1974;23:2983-3000.
54. Sayer LM, Singh MP, Kokil PB, Wang F. Non-electron-transfer quinone-mediated oxidative cleavage of cyclopropylamines. Implications regarding their utility as probes of enzyme mechanism. J Org Chem 1991;56:1353-1355.
55. Shah MA, Trackman PC, Gallop PM, Kagan HM. Reaction of lysyl oxidase with trans-2-phenylcyclopropylamine. J Biol Chem 1993;268:11580-11585.
56. Roh JH, Suzuki H, Azakami H, Yamashita M, Murooka Y, Kumagai H. Purification, characterization, and crystallization of monoamine oxidase from Escherichia coli K-12. Biosci Biotechnol Biochem 1994;58:1652-1656.
57. Saysell CG, Tambyrajah WS, Murray JM, Wilmot CM, Phillips SE, McPherson MJ, Knowles PF. Probing the catalytic mechanism of Escherichia coli amine oxidase using mutational variants and a reversible inhibitor as a substrate analogue. Biochem J 2002;365:809-816.
58. Shepard EM, Heggem H, Juda GA, Dooley DM. Inhibition of six copper-containing amine oxidases by the antidepressant drug tranylcypromine. Biochim Biophys Acta 2003;1647:252-259.
59. Yoshida S, Meyer OG, Rosen TC, Haufe G, Ye S, Sloan MJ, Kirk KL. Fluorinated phenylcyclopropylamines. 1. Synthesis and effect of fluorine substitution at the cyclopropane ring on inhibition of microbial tyramine oxidase. J Med Chem 2004;47:1796-1806.
60. Zajoncová L, Frébort I, Luhová L, Sebela M, Galuszka P, Pec P. Comparison of kinetic properties of amine oxidases from sainfoin and lentil and immunochemical characterization of copper/quinoprotein amine oxidases. Biochem Mol Biol Int 1999;47:47-61.
61. Kiplinger JL, Richmond TG, Osterberg CE. Activation of carbon-fluorine bonds by metal complexes. Chem Rev 1994;94:373-431.
62. Plenio H. The coordination chemistry of the CF unit in fluorocarbons. Chem Rev 1997;97:3363-3384.
63. Rosen TC, Yoshida S, Fröhlich R, Kirk KL, Haufe G. Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxidase. J Med Chem 2004;47:5860-5871.
64. Hruschka S, Yoshida S, Kirk KL, Haufe G. Fluorinated phenylcyclopropyl-amines. Part 6: Effects of electron withdrawing and donating aryl substituents on the inhibition of tyramine oxidase from arthrobacter sp. by diastereomeric 1-aryl-2-fluoro-cyclopropylamines. J Fluorine Chem 2008;129:875-880.
65. Yoshida S, Rosen TC, Meyer OG, Sloan MJ, Ye S, Haufe G, Kirk KL. Fluorinated phenylcyclopropylamines. Part 3: Inhibition of monoamine oxidase A and B. Bioorg Med Chem 2004;12:2645-2652.
66. Ye S, Yoshida S, Fröhlich R, Haufe G, Kirk KL. Fluorinated phenylcyclopropylamines. Part 4: Effects of aryl substituents and stereochemistry on the inhibition of monoamine oxidases by 1-aryl-2-fluoro-cyclopropylamines. Bioorg Med Chem 2005;13:2489-2499.
67. Hruschka S, Rosen TC, Yoshida S, Kirk KL, Fröhlich R, Wibbeling B, Haufe G. Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines. Bioorg Med Chem 2008;16:7148-7166.
68. Rosen TC, Yoshida S, Kirk KL, Haufe G. Fluorinated phenylcyclopropylamines as inhibitors of monoamine oxidases. Chem Bio Chem 2004;5:1033-1043.
69. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119:941-951.
70. Karytinos A, Forneris F, Profumo A, Ciossani G, Battaglioli E, Binda C, Mattevi A. A novel mammalian flavin-dependent histone demethylase. J Biol Chem 2009;284:17775-17782.
71. Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005;437:432-435.
72. Yang Z, Jiang J, Stewart DM, Qi S, Yamane K, Li J, Zhang Y, Wong J. AOF1 is a histone H3K4 demethylase possessing demethylase activity-independent repression function. Cell Res 2010;20:276-287.
73. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schüle R, Eggert A, Buettner R, Kirfel J. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Res 2009;69:2065-2071.
74. Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, Kirfel J. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010;31:512-520.
75. Gu H, Roizman B. Engagement of the lysine-specific demethylase/HDAC1/CoREST/REST complex by herpes simplex virus 1. J Virol 2009;83:4376-4385.
76. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by the lysine demethylase LSD1. Nature 2007;449:105-108.
77. Suzuki T, Miyata N. Lysine demethylases inhibitors. J Med Chem 2011;54:8236-8250.
78. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 2006;13:563-567.
79. Gooden DM, Schmidt DM, Pollock JA, Kabadi AM, McCafferty DG. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B. Bioorg Med Chem Lett 2008;18:3047-3051.
80. Benelkebir H, Hodgkinson C, Duriez PJ, Hayden AL, Bulleid RA, Crabb SJ, Packham G, Ganesan A. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. Bioorg Med Chem 2011;19:3709-3716.
81. Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 2009;131:17536-17537.
82. Yang M, Culhane JC, Szewczuk LM, Jalili P, Ball HL, Machius M, Cole PA, Yu H. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry 2007;46:8058-8065.
83. Yang M, Culhane JC, Szewczuk LM, Gocke CB, Brautigam CA, Tomchick DR, Machius M, Cole PA, Yu H. Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat Struct Mol Biol 2007;14:535-539.
84. Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T. Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 2008;105:5739-5744.
85. Ogasawara D, Suzuki T, Mino K, Ueda R, Khan MN, Matsubara T, Koseki K, Hasegawa M, Sasaki R, Nakagawa H, Mizukami T, Miyata N. Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. Bioorg Med Chem 2011;19:3702-3708.
86. Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T. Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA 2008;105:5739-5744.
87. De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A. Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci USA 2005;102:12684-1289.
88. Edmondson DE, De Colibus L, Binda C, Li M, Mattevi A. New insights into the structures and functions of human monoamine oxidases A and B. J Neural Transm 2007;114:703-705.
89. Mimasu S, Umezawa N, Sato S, Higuchi T, Umehara T, Yokoyama S. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 2010;49:6494-6503.
90. Müller K, Faeh C, Diederich F. Fluorine in pharmaceuticals: Looking beyond intuition. Science 2007;317:1881-1886.
91. Guibourt N, Ortega MA, Castro-Palomino LJ. Patent Appl. WO 2010043721; 2010.
92. Guibourt N, Ortega MA, Castro-Palomino LJ. Patent Appl. WO 2010084160; 2010.
93. Ortega MA, Castro-Palomino LJ, Fyfe MCT. Patent Appl. WO 2011035941; 2011.
94. Neelamegam R, Ricq RE, Malvaez M, Patnaik D, Norton S, Carlin SM, Hill IT, Wood MA, Haggarty SJ, Hooker M. Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem Neurosci 2012;3:120-128.
95. Goeptar AR, Scheerens H, Vermeulen NP. Oxygen and xenobiotic reductase activities of cytochrome P450. Crit Rev Toxicol 1995;25:25-65.
96. Arlt VM, Levová K, Bárta F, Shi Z, Evans JD, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Stiborová M. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: Studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice. Chem Res Toxicol 2011;24:1710-1719.
97. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985;13:443-448.
98. Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 1997;25:1130-1136.
99. Draper AJ, Madan A, Parkinson A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 1997;341:47-61.
100. Taavitsainen P, Juvonen R, Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metabol Dispos 2001;29:217-222.
101. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8:794-805.
102. Tanaka D, Tsuda Y, Shiyama T, Nishimura T, Chiyo N, Tomanaga Y, Sawada N, Mimoto T, Kusunose N. A practical use of ligand efficiency indices out of the fragment-based approach: Ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors. J Med Chem 2011;54:851-857.
103. Das K, Bauman JD, Rim AS, Dharia C, Clark AD Jr, Camarasa MJ, Balzarini J, Arnold E. Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. J Med Chem 2011;54:2727-2737.
104. Högberg M, Sahlberg C, Engelhardt P, Noréen R, Kangasmetsä J, Johansson NG, Oberg B, Vrang L, Zhang H, Sahlberg BL, Unge T, Lövgren S, Fridborg K, Bäckbro K. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. J Med Chem 1999;42:4150-4160.
105. Ingham PW, McMahon AP. Hedgehog signaling in animal development: Paradigms and principles. Genes Dev 2001;15:3059-3087.
106. Xie J. Hedgehog signaling pathway: Development of antagonists for cancer therapy. Curr Oncol Rep 2008;10:107-113.
107. Gallinari P, Filocamo G, Jones P, Pazzaglia S, Steinkuhler C. Smoothened antagonists: A promising new class of antitumor agents. Exp Opin Drug Discov 2009;4:525-544.
108. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297:1559-1561.
109. Malancona S, Altamura S, Filocamo G, Kinzel O, Hernando JI, Rowley M, Scarpelli R, Steinkühler C, Jones P. Identification of MK-5710 ((8aS)-8a-methyl-1, 3-dioxo-2-[(1S, 2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1, 5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 1. Bioorg Med Chem Lett 2011;21:4422-428.
110. Kinzel O, Alfieri A, Altamura S, Brunetti M, Bufali S, Colaceci F, Ferrigno F, Filocamo G, Fonsi M, Gallinari P, Malancona S, Hernando JI, Monteagudo E, Orsale MV, Palumbi MC, Pucci V, Rowley M, Sasso R, Scarpelli R, Steinkühler C, Jones P. Identification of MK-5710 ((8aS)-8a-methyl-1, 3-dioxo-2-[(1S, 2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1, 5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2. Bioorg Med Chem Lett 2011;21:4429-4435.
111. Ritter CA, Artega CL. The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors. Semin Oncol 2003;30:3-11.
112. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
113. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004;11:689-708.
114. Gibson KH, Grundy W, Godfrey AA, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Barker AJ, Brown DS. Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines. Bioorg Med Chem Lett 1997;7:2723-2728.
115. Pannala M, Kher S, Wilson N, Gaudette J, Sircar I, Zhang SH, Bakhirev A, Yang G, Yuen P, Gorcsan F, Sakurai N, Barbosa M, Cheng JF. Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett 2007;17:5978-5982.
116. Wolfson JS, Hooper DC. The fluoroquinolones: Structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985;28:581-586.
117. Janknegt R. Fluorinated quinolones. Pharma Weekblad 1986;8:1-21.
118. Hooper DC. Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin Infect Dis 2001;32:S9-S15.
119. Mitscher LA, Sharma PN, Chu DT, Shen LL, Pernet AG. Chiral DNA gyrase inhibitors. 1. Synthesis and antimicrobial activity of the enantiomers of 6-fluoro-7-(1-piperazinyl)-1-(2′-trans-phenyl-1′-cyclopropyl)-1, 4-dihydro-4-oxoquinoline-3-carboxylic acid. J Med Chem 1986;29:2044-2047.
120. Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003;46:2795-2812.
121. Carson MJ, Thomas EA, Danielson PE, Sutcliffe JG. The 5HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: A mechanism for neuronal suppression of reactive astrocytes. Glia 1996;17:317-326.
122. Nichols DE. Hallucinogens. Pharmacol Ther 2004;101:131-181.
123. Hutcheson JD, Setola V, Roth BL, Merryman WD. Serotonin receptors and heart valve disease-It was meant 2B. Pharmacol Ther 2011;132:146-157.
124. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
125. Booth RG, Fang L, Huang Y, Wilczynski A, Sivendran S. 1R, 3S)-(-)-trans-PAT: A novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. Eur J Pharmacol 2009;615:1-9.
126. Dunlop J, Marquis KL, Lim HK, Leung L, Kao J, Cheesman C, Rosenzweig-Lipson S. Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Rev 2006;12:167-177.
127. Arvidsson LE, Johansson AM, Hacksell U, Nilsson JL, Svensson K, Hjorth S, Magnusson T, Carlsson A, Lindberg P, Andersson B, Sanchez D, Wickstrom H, Sundell S. N, N-dialkylated monophenolic trans-2-phenylcyclopropylamines: Novel central 5-hydroxytryptamine receptor agonists. J Med Chem 1988;31:92-99.
128. Vallgårda J, Appelberg U, Arvidsson LE, Hjorth S, Svensson BE, Hacksell U. trans-2-Aryl-N, N-dipropylcyclopropylamines: Synthesis and interactions with 5-HT(1A) receptors. J Med Chem 1996;39:1485-1493.
129. Cho SJ, Jensen NH, Kurome T, Kadari S, Manzano ML, Malberg JE, Caldarone B, Roth BL, Kozikowski AP. Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: Identification of drugs with antidepressant-like action. J Med Chem 2009;52:1885-1902.
130. Kozikowski AP, Cho SJ, Jensen NH, Allen JA, Svennebring AM, Roth BL. HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia. Chem Med Chem 2010;5:1221-1221.
131. 2B activity. ACS Med Chem Lett 2011;2:929-932.
132. Murugappa S, Kunapuli SP. The role of ADP receptors in platelet function. Front Biosci 2006;11:1977-1986.
133. Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. The platelet ATP and ADP receptors. Curr Pharm Des 2006;12:859-875.
134. 1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation. Thromb Haemostasis 1999;81:775-781.
135. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999;19:2281-2285.
136. Barnard EA, Simon J. An elusive receptor is finally caught: P2Y(12′), an important drug target in platelets. Trends Pharmacol Sci 2001;22:388-391.
137. Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG, Hunt SF, Ince F, Ingall AH, Kirk IP, Leeson PD, Leff P, Lewis RJ, Martin BP, McGinnity DF, Mortimore MP, Paine SW, Pairaudeau G, Patel A, Rigby AJ, Riley RJ, Teobald BJ, Tomlinson W, Webborn PJ, Willis PA. From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007;17:6013-6018.
138. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.
139. Ye H, Chen C, Zhang HC, Haertlein B, Parry TJ, Damiano BP, Maryanoff BE. Carba-nucleosides as potent antagonists of the adenosine 5′-diphosphate (ADP) purinergic receptor (P2Y12 on human platelets. Chem Med Chem 2008;3:732-736.
140. McCann DJ, Weissman AD, Su TP. Sigma-1 and sigma-2 sites in rat brain: Comparison of regional, ontogenetic, and subcellular patterns. Synapse 1995;17:182-189.
141. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995;55:408-413.
142. Hayashi T, Su TP. An update on the development of drugs for neuropsychiatric disorders: Focusing on the sigma 1 receptor ligand. Expert Opin Ther Targets 2008;12:45-58.
143. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007;131:596-610.
144. Glennon RA. Pharmacophore identification for sigma-1 (sigma1) receptor binding: Application of the "deconstruction-reconstruction-elaboration" approach. Mini-Rev Med Chem 2005;5:927-940.
145. Brown C, Fezoui M, Selig WM, Schwartz CE, Ellis JL. Antitussive activity of sigma-1 receptor agonists in the guinea-pig. Br J Pharmacol 2004;141:233-240.
146. Valade A, Cross SB, Brown C, Detrait E, Ene E, Gillard M, Guyaux M, Lamberty Y, Maguire M, Namdev N, Provins L, Schwartz E, Vermeiren C. Discovery of novel selective Sigma-1 ligands as cognitive enhancers. Med Chem Commun 2011;2:655-660.
147. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517-532.
148. Stavropoulos P, Blobel G, Hoelz A. Crystal structure and mechanism of human lysine-specific demethylase-1. Nat Struct Mol Biol 2006;13:626-632.